Men's Health Briefing: October 13, 2026

The short version

A quiet news day. We found no new FDA, DEA, FTC, or federal telehealth actions on men's health since our October 12 briefing.

Health topics: a new meta-analysis links sleep apnea and other sleep disorders to worse erectile function and lower testosterone. It shows an association, not proof of cause.

Health topics: a review of 13 trials found fenugreek "testosterone boosters" raised total testosterone only slightly, with very low certainty and no clear change in free testosterone.

The DEA's final telehealth prescribing rule has not been published as of this check. The temporary rules expire December 31, 2026.

This week

We checked FDA, DEA, and FTC announcements, federal telehealth policy, research news, and news on the providers in our directory for October 12 – 13. We found nothing in that window that we could confirm with a primary source and that changes treatment access, cost, safety, or health data for men's health readers. The most recent FDA press announcement we found is dated October 5. The FTC's October 13 releases concern a sextortion-relief scheme and a request to hold Martin Shkreli in contempt of a pharmaceutical industry ban; neither concerns men's health products or telehealth. Medicare telehealth coverage remains in place through December 31, 2027. For the previous check, see our October 12 briefing.

Health topics

ED & PDE5 inhibitorsSeptember 7, 2026

Sleep disorders linked to worse erections and lower testosterone in a new meta-analysis

A systematic review and meta-analysis in the Archivio Italiano di Urologia, Andrologia, published online September 7, 2026, pooled nine studies of men with obstructive sleep apnea (OSA) or shift-work sleep disorder. Seven studies (913 men) fed the erectile function analysis, and a smaller set (325 men) fed the hormone results. The pooled average erectile function score was about 16 on the IIEF scale, which the authors describe as moderate ED. Men with OSA scored lower (about 14.4) than men with shift-work sleep disorder (about 17.5), and their testosterone was lower (roughly 7 to 9 nmol/L versus about 20 nmol/L). The authors also report that even mild OSA was associated with reduced erectile performance.

The limits matter. The studies differed widely (heterogeneity was very high, I² of 97%), they used different measurement tools, and the abstract gives no confidence intervals. This kind of analysis shows an association. It can't show that treating sleep apnea restores erections or testosterone. We read the abstract; the full text is paywalled.

What it means for youED has many causes, and sleep apnea is a common, treatable one that often goes undiagnosed. If you snore, wake unrefreshed, or are very sleepy in the daytime, mention it to your doctor along with the ED. A sleep test is the only way to know. Our STOP-BANG screener can help you decide whether to ask.

Sources: PubMed record · Related: Sleep apnea in men · ED and low testosterone

Fitness & recoveryAugust 19, 2026

Fenugreek "testosterone boosters": a small rise in total testosterone, with very low certainty

A systematic review and meta-analysis in Frontiers in Nutrition, published August 19, 2026, pooled randomized, placebo-controlled trials of oral fenugreek in adult men. Of 13 trials, eight reported primary testosterone data in 637 randomized men, mostly healthy or resistance-trained men taking 500 to 600 mg a day for 8 to 12 weeks. Most trials did not enroll men with confirmed low testosterone. Across six studies (385 men), total testosterone was slightly higher with fenugreek (standardized mean difference 0.25, 95% confidence interval 0.02 to 0.48). Across five studies (334 men), free testosterone showed no clear change (0.08, interval -0.48 to 0.63). The authors rated the certainty of the evidence as very low for both, and none of the trials was at low risk of bias overall.

The review's authors note that industry funding or company involvement was common among the included trials, safety reporting was incomplete, follow-up was short, and the studies measured hormone levels rather than symptoms, fertility, or semen quality. They reported no conflicts of interest of their own. Their conclusion: current evidence does not support testosterone-boosting claims.

What it means for youA statistically small change on a blood test isn't the same as feeling better, and these trials mostly weren't in men with low testosterone. If you suspect low testosterone, the useful step is a morning blood test with your doctor, not a supplement. Tell your clinician which supplements you take.

Sources: PubMed record · Full text · Related: Supplements: what actually works · Low testosterone symptoms

What we're watching

The DEA's final telemedicine rule, which was sent to the White House Office of Management and Budget on August 25, 2026. The federal regulatory agenda lists November 2026 for final action, ahead of the December 31 expiration of the temporary telehealth prescribing rules. We found no publication of the rule as of October 13. If you get testosterone through a telehealth-only provider, nothing has changed yet. (NASCSA)

Testosterone for women, following the FDA's September 17 public workshop. Comments are open through October 19, 2026. (Public comment docket)

Testosterone label updates as manufacturers revise their prescribing information after the FDA's June 2026 request. See our TRT guide for what the research shows.

Compounded GLP-1 enforcement, including any follow-up to the FDA's September 18 warning letter to Empower Pharmacy, which the FDA made public on September 22. A warning letter states the FDA's concerns and is not a final finding. (Buchanan Ingersoll & Rooney · Related: our GLP-1 guide)

The FTC's case against Hims & Hers, filed July 29, 2026. The allegations have not been proven, and the company has said it disputes them. (FTC case page · Our Hims review)